BioCentury | May 13, 2020
Product Development

Gilead secures global access to remdesivir via generic manufacturing deals

The first manufacturing deals for Gilead’s remdesivir, plus a series of grants for institutions across Europe to develop COVID-19 diagnostics and therapeutics, highlight the importance of global collaboration to tackle the pandemic. Gilead Sciences Inc....
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BioCentury | Mar 18, 2020
Product Development

COVID-19 roundup: BioNTech, Pfizer co-developing vaccine, plus updates from Regeneron, Novartis, CureVac, Fujifilm and CanSino

Biopharma companies stretching from Asia to the U.S. and Europe Tuesday announced a flurry of deals, new initiatives and clinical updates for therapeutic and vaccine approaches to address the COVID-19 pandemic, including a partnership between...
BioCentury | Feb 28, 2020
Product Development

WHO reports China making 1.6M COVID-19 diagnostic kits per week, describes therapy and vaccine R&D priorities

A WHO report on a Feb. 16-24 mission to China to assess the COVID-19 outbreak summarizes the situation on the ground, highlights countermeasure R&D initiatives, challenges and needs, and identifies critical knowledge gaps. What stands...
BioCentury | Feb 15, 2020
Product Development

Preclinical potencies of clinical COVID-19 candidates

Among the several dozen agents in clinical testing for COVID-19, in vitro data against the new coronavirus have only been reported for four, and they support the WHO’s prioritization of remdesivir from Gilead Sciences Inc....
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Week In Review | Jun 8, 2018
Company News

DRC approves compassionate use of investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
BC Extra | Jun 6, 2018
Company News

DRC approves investigational Ebola treatments

A Democratic Republic of the Congo ethics committee approved the use of five investigational Ebola therapies under compassionate use and expanded access. The World Health Organization said four of the five approved products are in...
BC Extra | May 31, 2018
Company News

Regeneron sends experimental Ebola therapy to Congo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it began shipping its investigational Ebola antibody cocktail REGN-EB3 (REGN3470-3471-3479) to the Democratic Republic of the Congo (DRC). REGN-EB3 was one of several experimental therapies considered for the treatment of...
BC Week In Review | Mar 23, 2015
Clinical News

Favipiravir: Completed Phase III enrollment

MediVector completed enrollment of 2,021 adults with uncomplicated influenza in the 2 double-blind, placebo-controlled, international Phase III FAVOR trials evaluating oral favipiravir for 5 days. Patients will receive 1,800 mg twice daily on day 1...
Items per page:
1 - 10 of 26